文献速递肝病

血清代谢物在非酒精性脂肪性肝病衍生与验证队列中检测进展性纤维化

Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
PubMed 文献 · Gut · 2018-12-19

该研究为横断面分析,在156例经活检证实的非酒精性脂肪性肝病(NAFLD)患者衍生队列中,10种血清代谢物组合检测进展性纤维化的AUROC为0.94,高于FIB-4的0.78和NAFLD纤维化评分(NFS)的0.84;在两个独立验证队列(MRI弹性成像142例和活检59例)中c-statistic分别为0.94和0.84。

要点

  • 10种血清代谢物组合检测进展性纤维化的AUROC为0.94,优于FIB-4和NFS。
  • 在MRI弹性成像验证队列中c-statistic为0.94,在活检验证队列中为0.84。
  • 该概念验证研究提示基于血液的无创诊断试验检测进展性纤维化性能优良。

核心结论

  • 10种血清代谢物组合在衍生队列和两个独立验证队列中检测进展性纤维化表现出优良的区分能力,诊断准确性高于FIB-4指数和NFS。
  • 该概念验证研究证明基于血液的无创诊断试验检测进展性纤维化可提供优良的性能特征。

研究设计与样本

  • 本研究为前瞻性衍生队列的横断面分析,纳入156例特征明确的活检证实NAFLD患者。
  • 验证队列包括142例采用MRI弹性成像(MRE)评估的患者和59例活检证实NAFLD并接受非靶向血清代谢组分析的患者。

主要发现

  • 在衍生队列中,23例(15%)存在进展性纤维化;经错误发现率校正后,652种分析代谢物中有32种与进展性纤维化显著相关。
  • 前10位代谢物包括8种脂质(5α-雄甾烷-3β单硫酸盐、孕二醇-3-葡萄糖醛酸苷、雄酮硫酸盐、表雄酮硫酸盐、棕榈油酸、脱氢异雄酮硫酸盐、5α-雄甾烷-3β二硫酸盐、甘胆酸盐)、1种氨基酸(牛磺酸)和1种碳水化合物(岩藻糖)。
  • 前10位代谢物组合检测进展性纤维化的AUROC为0.94(95%CI 0.897至0.982),高于FIB-4的0.78(95%CI 0.674至0.891),p=0.002;也高于NFS的0.84(95%CI 0.724至0.929),p=0.017。
  • 在MRE评估的独立验证队列中c-statistic为0.94,在肝活检评估的独立验证队列中c-statistic为0.84。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Non-invasive and accurate diagnostic tests for the screening of disease severity in non-alcoholic fatty liver disease (NAFLD) remain a major unmet need. Therefore, we aimed to examine if a combination of serum metabolites can accurately predict the presence of advanced fibrosis. DESIGN: This is a cross-sectional analysis of a prospective derivation cohort including 156 well-characterised patients with biopsy-proven NAFLD and two validation cohorts, including (1) 142 patients assessed using MRI elastography (MRE) and(2) 59 patients with biopsy-proven NAFLD with untargeted serum metabolome profiling. RESULTS: In the derivation cohort, 23 participants (15%) had advanced fibrosis and 32 of 652 analysed metabolites were significantly associated with advanced fibrosis after false-discovery rate adjustment. Among the top 10 metabolites, 8 lipids (5alpha-androstan-3beta monosulfate, pregnanediol-3-glucuronide, androsterone sulfate, epiandrosterone sulfate, palmitoleate, dehydroisoandrosterone sulfate, 5alpha-androstan-3beta disulfate, glycocholate), one amino acid (taurine) and one carbohydrate (fucose) were identified. The combined area under the receiver operating characteristic curve (AUROC) of the top 10 metabolite panel was higher than FIB--4 and NAFLD Fibrosis Score (NFS) for the detection of advanced fibrosis: 0.94 (95% CI 0.897 to 0.982) versus 0.78 (95% CI0.674 to 0.891), p=0.002 and versus 0.84 (95% CI 0.724 to 0.929), p=0.017, respectively. The AUROC of the top 10 metabolite panel remained excellent in the independent validation cohorts assessed by MRE or liver biopsy: c-statistic of 0.94 and 0.84, respectively. CONCLUSION: A combination of 10 serum metabolites demonstrated excellent discriminatory ability for the detection of advanced fibrosis in an derivation and two independent validation cohorts with greater diagnostic accuracy than the FIB-4-index and NFS. This proof-of-concept study demonstrates that a non-invasive blood-based diagnostic test can provide excellent performance characteristics for the detection of advanced fibrosis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Caussy C, Ajmera VH, Puri P, et al. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut. 2018. PMID: 30567742. doi:10.1136/gutjnl-2018-317584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。